Moderna Falls 7.8% Ahead of Cancer Vaccine Data as President Hoge's $17M Planned Sales Surface

MRNA fell 7.8% on Friday to $218.01, according to MarketBeat and SentiSense data, after trading as low as $208.92. Volume ran 73% above the average session. Seeking Alpha reported the stock was down nearly 10% in afternoon trading as investors positioned ahead of next week's detailed cancer vaccine data.

The insider sales in the headlines all came from one person. Filings show President Stephen Hoge sold 39,224 shares on October 14 at $213.48 and 39,145 shares on October 15 at an average of $220.72, about $17 million in total. Both sales were made under a Rule 10b5-1 trading plan adopted on June 15, 2026, which means they were scheduled months in advance rather than timed to Friday's move. Hoge also exercised options on both days and still holds 1,636,565 shares directly.

The catalyst investors are actually trading is the INTerpath-001 Phase 3 study of Moderna's individualized neoantigen therapy, which will be presented at the ESMO Presidential Symposium on Saturday, October 24, at 10:30 a.m. EDT, followed by a company webcast at 1:00 p.m. EDT. Topline results announced on August 19 met the study's recurrence-free survival endpoint against Keytruda alone, and the stock fell about 20% the next day as investors weighed the details. The shares have climbed sharply since then, which raises the bar for the full data.

What to watch: the size and durability of the benefit in the ESMO presentation, any safety signals, and commentary on the regulatory path. Further planned sales by executives are possible under existing trading plans and would not by themselves say anything new about the data.